OLIGOMERIX
Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.
OLIGOMERIX
Industry:
Biotechnology Ediscovery Medical
Founded:
2006-01-01
Address:
Bronx, New York, United States
Country:
United States
Website Url:
http://www.oligomerix.com
Total Employee:
1+
Status:
Active
Contact:
(212) 568-0365
Email Addresses:
[email protected]
Total Funding:
15.13 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Current Employees Featured
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Oligomerix
Small Business Innovation Research
Small Business Innovation Research investment in Grant - Oligomerix
National Institutes of Health
National Institutes of Health investment in Grant - Oligomerix
Wheatley MedTech Partners
Wheatley MedTech Partners investment in Series A - Oligomerix
Wheatley Partners
Wheatley Partners investment in Series A - Oligomerix
Durand Venture Associates
Durand Venture Associates investment in Series A - Oligomerix
Official Site Inspections
http://www.oligomerix.com
- Host name: web2.axxiem.com
- IP address: 34.230.198.252
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Oligomerix"
About - Oligomerix
Oligomerix seeks to improve the lives of patients with neurodegenerative diseases by discovering and developing a portfolio of disease-modifying, oral small molecule therapeutics that are simple to use. Oligomerix is a biotech …See details»
Oligomerix - Crunchbase Company Profile & Funding
Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research that allows rapid generation of …See details»
Oligomerix Announces Key Organizational Changes in …
Jul 20, 2022 Oligomerix announces several organizational changes reflecting the transition to a clinical-stage pharmaceutical company. ... Dr. Erhardt’s primary focus will be to lead the organization into ...See details»
Management - Oligomerix
He recently joined Oligomerix in a part-time role managing all matters related to chemistry. Since 2014, he has been the Principal Consultant at EHC Solutions and Principal Chemistry …See details»
Oligomerix Company Profile 2024: Valuation, Funding …
Oligomerix General Information Description. Developer of small molecule therapeutics designed to treat Alzheimer's disease with an upstream approach. The company specializes in disease-modifying therapeutics for …See details»
Oligomerix, Inc - LinkedIn
Oligomerix, Inc | 870 followers on LinkedIn. Developing small molecule therapeutics targeting tau for rare neuro diseases and AD - clinical studies starting 2022 | Oligomerix is an emerging ...See details»
Oligomerix Company Profile - Craft
Oligomerix is a biotechnology company that develops disease-modifying and treatment therapeutics for neurodegenerative diseases. It offers target discovery and validation, drug …See details»
Oligomerix - Funding, Financials, Valuation & Investors - Crunchbase
Oligomerix is funded by 6 investors. National Institute on Aging and National Institutes of Health are the most recent investors. Oligomerix has a post-money valuation in the range of $10M to …See details»
Oligomerix, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Oligomerix has developed a platform of assays and small molecule inhibitors designed to block the initiation and progression of tau aggregation. The Company has initiated a Phase 1a …See details»
Oligomerix - Contacts, Employees, Board Members, Advisors
Oligomerix has 4 current employee profiles, including Co-Founder, CEO and Head, Discovery & Strategy James Moe. James Moe Co-Founder, CEO and Head, Discovery & Strategy Eliot J. …See details»
Oligomerix Announces Key Organizational Changes in Transition …
2 Westchester Park Drive STE 208 White Plains, NY 10604 Tel: 212-568-0365 Ext. 104 www.oligomerix.com Oligomerix Announces Key Organizational Changes in Transition to …See details»
Oligomerix - Products, Competitors, Financials, Employees, …
Oligomerix is a biotechnology company focused on developing therapeutics for neurodegenerative diseases associated with tau protein abnormalities. Use the CB Insights …See details»
Oligomerix - Overview, News & Similar companies | ZoomInfo.com
Feb 2, 2023 Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010 WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Oligomerix, Inc., a privately held …See details»
Oligomerix, Inc - Company Profile & Staff Directory - ContactOut
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging …See details»
NIA Small Business Showcase: Oligomerix - National Institute on …
Oligomerix® developed a multi-faceted commercialization strategy that includes all key marketing elements such as extensive market research, development of a Target Product Profile (TPP), …See details»
Board of Directors - Oligomerix
Prior to founding Oligomerix, he was Director of Product Development at Pyrosequencing, Senior Molecular Biologist at Spire Biomedical, and Director of Product Development at Q-RNA, Inc. …See details»
Oligomerix Company Profile: Overview and Full News Analysis
Oligomerix is a biotechnology company located in New York that specializes in developing disease-modifying and treatment therapeutics for neurodegenerative diseases associated with …See details»
About Oligomerix, Inc.
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010 -- Phase 1a study will evaluate the safety and tolerability of OLX-07010 in healthy volunteers -- …See details»
Pipeline - Oligomerix
Oligomerix has advanced its lead small molecule tau self-association inhibitor, known as OLX-07010, into first-in-human phase 1a clinical trials. This achievement is the result of a focus on …See details»